News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care L.A. McKeown May 17, 2024
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement L.A. McKeown April 27, 2022
News Daily News Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol Michael O'Riordan March 15, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT Michael O'Riordan October 04, 2021